World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3708)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

1830

Figures (1-3)

213

Tables (1-3)

231

Sum=2349

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

166

Download

461

Sum=627

Publishing Process of This Article

Item

Count

Browse

169

Download

431

Sum=600

Jan 28, 2024 (publication date) through Jan 31, 2025

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Cao YZ, Zheng GL, Zhang TQ, Shao HY, Pan JY, Huang ZL, Zuo MX. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis. World J Gastroenterol 2024; 30(4): 318-331 [PMID: 38313229 DOI: 10.3748/wjg.v30.i4.318]
URL:	https://www.wjgnet.com/1007-9327/full/v30/i4/318.htm

Number	Citing Articles
1	Liyuan Hao, Shenghao Li, Fanghang Ye, Hengyi Wang, Yuxin Zhong, Xiaoyi Zhang, Xiaoyu Hu, Xiaopeng Huang. The current status and future of targeted-immune combination for hepatocellular carcinoma. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1418965
2	Andrzej S Tarnawski. Editor-in-Chief articles of choice and comments from January to June 2024. World Journal of Gastroenterology 2024; 30(34): 3875-3882 doi: 10.3748/wjg.v30.i34.3875 Abstract(250) \| Core Tip(253) \| Full Article(HTML)(519) \| Full Article with Cover (PDF)-639K(39) \| Audio-785K(6) \| Peer-Review Report-230K(24) \| Answering Reviewers-209K(30) \| Full Article (PDF)-410K(41) \| Full Article (XML)-117K(27) \| Times Cited (0) \| Total Visits (1639) \| Open
3	Yu-zhe Cao, Jia-yu Pan, Guang-lei Zheng, Chao An, Meng-Xuan Zuo. Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma. Cancer Immunology, Immunotherapy 2024; 74(1) doi: 10.1007/s00262-024-03872-6
4	Georgia Sofia Karachaliou, Nikolaos Dimitrokallis, Dimitrios P Moris. Downstaging strategies for unresectable hepatocellular carcinoma. World Journal of Gastroenterology 2024; 30(20): 2731-2733 doi: 10.3748/wjg.v30.i20.2731 Abstract(301) \| Core Tip(367) \| Full Article(HTML)(1651) \| Full Article with Cover (PDF)-752K(47) \| Audio-745K(3) \| Peer-Review Report-169K(30) \| Answering Reviewers-25K(30) \| Full Article (PDF)-324K(99) \| Full Article (XML)-22K(32) \| Times Cited (3) \| Total Visits (2993) \| Open
5	Hengzhou Zhu, Wenyue Zhao, Haoyan Chen, Xiaodan Zhu, Jianliang You, Chunhui Jin. Evaluation of the effectiveness and safety of combining PD-1/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1468440
6	Kyoko Oura, Asahiro Morishita, Tomoko Tadokoro, Koji Fujita, Joji Tani, Hideki Kobara. Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2024; 25(24): 13590 doi: 10.3390/ijms252413590